Literature DB >> 8420834

HLA-DPB1 alleles in a population from south China.

M Falco1, Y Sun, M A Fernandez-Viña, P Stastny.   

Abstract

Using the polymerase chain reaction (PCR) and hybridization with oligonucleotide probes, we analyzed the distribution of DPB1 alleles in 99 healthy unrelated individuals from the city of Guangzhou (Canton), South China. Twelve different DPB1 alleles were found in this panel. The most common allele was DPB1*0501 (62.6%). Other major alleles detected included DPB1*02 (DPB1*0201 and DPB1*0202), DPB1*1301, DPB1*0401, and a recently described allele, designated DPB1*2101. The hybridization pattern of DPB1*2101 showed that this allele shared sequences with DPB1*0301 and DPB1*0601 in the A and F hypervariable regions, while the C, D, and E regions were identical to those of DPB1*0202. DPB1*2101 was observed in 11% of the subjects tested. It was found to be in strong linkage disequilibrium with DRB1*1202. In family studies, segregation of the haplotype DRB1*1202, DRB3*0301, DQA1*0601, DQB1*0301, DPB1*2101 was observed. The second exon of DPB1*2101 was sequenced from codon 8 to codon 90 and the sequence, inferred from the pattern of hybridization, was confirmed. DPB1*0301, DPB1*0402, DPB1*0101, DPB1*1401, DPB1*1901, and another recently recognized allele, now designated DPB1*2401, were detected with low frequencies. DPB1*2401 had the same hybridization pattern as DPB1*0501 except for a probe that matches codons 85-90. In this region, DPB1*2401 encoded the amino acid sequence GPMTLQ instead of EAVTLQ as in DPB1*0501.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420834     DOI: 10.1007/bf00187450

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  10 in total

1.  Nomenclature for factors of the HLA system, 1991. WHO Nomenclature Committee for factors of the HLA system.

Authors:  J G Bodmer; S G Marsh; E D Albert; W F Bodmer; B Dupont; H A Erlich; B Mach; W R Mayr; P Parham; T Sasazuki
Journal:  Tissue Antigens       Date:  1992-04

2.  DNA typing for class II HLA antigens with allele-specific or group-specific amplification. III. Typing for 24 alleles of HLA-DP.

Authors:  M Fernandez-Vina; M E Moraes; P Stastny
Journal:  Hum Immunol       Date:  1991-01       Impact factor: 2.850

3.  New DPB1 alleles.

Authors:  H O Madsen; L P Ryder; L Fugger; N Odum; B K Jakobsen; A Svejgaard
Journal:  Tissue Antigens       Date:  1992-02

4.  Comparison of HLA class II alleles in Gypsy and Czech populations by DNA typing with oligonucleotide probes.

Authors:  M Cerná; M Fernandez-Viña; E Ivásková; P Stastny
Journal:  Tissue Antigens       Date:  1992-03

5.  Polymorphism, recombination, and linkage disequilibrium within the HLA class II region.

Authors:  A B Begovich; G R McClure; V C Suraj; R C Helmuth; N Fildes; T L Bugawan; H A Erlich; W Klitz
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

6.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

7.  A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules.

Authors:  J H Brown; T Jardetzky; M A Saper; B Samraoui; P J Bjorkman; D C Wiley
Journal:  Nature       Date:  1988-04-28       Impact factor: 49.962

8.  The polymorphism of HLA antigens in the Chinese.

Authors:  T D Lee; T M Zhao; R Mickey; Y P Sun; G Lee; C X Song; D Z Cheng; S Zhou; S Q Ding; D X Cheng
Journal:  Tissue Antigens       Date:  1988-10

9.  DNA typing for HLA-DR, and -DP alleles in a Chinese population using the polymerase chain reaction (PCR) and oligonucleotide probes.

Authors:  X J Gao; Y P Sun; J B An; M Fernandez-Viña; J N Qou; L Lin; P Stastny
Journal:  Tissue Antigens       Date:  1991-07

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.